Page 1

Agilent Reports Second - Quarter Fiscal Year 2021 Financial Results Delivers Strong , Broad - Based Growth Raising Full - Year Outlook on Continued Company Momentum Exhibit 99.1 Highlights : • • • Revenue of $ 1.525 billion represents an increase of 23 % reported growth year - over - year , up 19 % on a core ( 1 ) basis . GAAP net income of $ 216 million , or 70 cents per share . Non - GAAP ( 2 ) net income of $ 299 million , or 97 cents per share . Completed the Resolution Bioscience acquisition . Full - year guidance raised with revenue now expected to be in the range of $ 6.15 billion to $ 6.21 billion and non - GAAP ( 3 ) earnings per share ( EPS ) of $ 4.09 to $ 4.14 . Third - quarter revenue expected to be in the range of $ 1.51 billion to $ 1.54 billion with non - GAAP ( 3 ) EPS of 97 cents to 99 cents . SANTA CLARA , Calif . , May 25 , 2021 - Agilent Technologies Inc. ( NYSE : A ) today reported revenue of $ 1.525 billion for the second quarter ended April 30 , 2021 , an increase of 23 % compared to the second quarter of 2020 and up 19 % on a core ( 1 ) basis . Second - quarter GAAP net income was $ 216 million , or 70 cents per share . This compares with $ 101 million , or 32 cents per share , in the second quarter of fiscal year 2020. Non - GAAP ( 2 ) net income was $ 299 million , or 97 cents per share compared with $ 223 million , or 71 cents per share , during the second quarter a year ago . " The Agilent team delivered an exceptional quarter , exceeding our revenue and earnings expectations , as our growth momentum continues , ” said Mike McMullen , Agilent president and CEO . “ Our very strong growth is broad - based across all end - markets , geographies and business groups . These results reflect our relentless customer focus , innovative solutions and excellent operational execution . Due to our strong- second quarter performance and expected continued momentum , we are raising our revenue and earnings outlook for the full year . " We also welcomed the Resolution Bioscience team to Agilent in Q2 , continuing our investment in high- growth markets as part of our ' build and buy ' growth strategy . " Financial Highlights Life Sciences and Applied Markets Group Second - quarter revenue of $ 674 million from Agilent's Life Sciences and Applied Markets Group ( LSAG ) was up 28 % year over year and 25 % on a core ( ¹ ) basis . LSAG's operating margin was 22.9 % . Agilent CrossLab Group 1